Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Giuseppe Ciaramella, insider at Beam Therapeutics

Giuseppe Ciaramella Insider Information

Insider of Beam Therapeutics
Giuseppe Ciaramella, Ph.D. has served as our Chief Scientific Officer since February 2018 and as our President and Chief Scientific Officer since January 2020. Dr. Ciaramella has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics, a biopharmaceutical company, from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, which technology formed the backbone of its authorized vaccine for the prevention of COVID-19. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, a biopharmaceutical company, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, a pharmaceutical company, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer, a biopharmaceutical company, in the U.K. where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London. Provided by Tagnifi.

What is Giuseppe Ciaramella's net worth?

The estimated net worth of Giuseppe Ciaramella is at least $4.07 million as of March 31st, 2022. Dr. Ciaramella owns 115,614 shares of Beam Therapeutics stock worth more than $4,068,457 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Ciaramella may own. Additionally, Dr. Ciaramella receives a salary of $746,240.00 as Insider at Beam Therapeutics. Learn More about Giuseppe Ciaramella's net worth.

How old is Giuseppe Ciaramella?

Dr. Ciaramella is currently 53 years old. There are 4 older executives and no younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics is Ms. Suzanne Fleming, Chief Accounting Officer, who is 61 years old. Learn More on Giuseppe Ciaramella's age.

What is Giuseppe Ciaramella's salary?

As the Insider of Beam Therapeutics Inc., Dr. Ciaramella earned a total compensation package of $6,852,786.00 in 2020. Dr. Ciaramella earned a salary of $469,363.00, options awards of $6,106,551.00, non-equity compensation of $267,188.00, and other compensation of $9,684.00.The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $906,770.00 per year. Learn More on Giuseppe Ciaramella's salary.

How do I contact Giuseppe Ciaramella?

The corporate mailing address for Dr. Ciaramella and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected] Learn More on Giuseppe Ciaramella's contact information.

Has Giuseppe Ciaramella been buying or selling shares of Beam Therapeutics?

Giuseppe Ciaramella has not been actively trading shares of Beam Therapeutics over the course of the past ninety days. As far as recent transactions, 0 shares of the business's stock in a transaction that occurred on Sunday, May 22nd. Learn More on Giuseppe Ciaramella's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 14 times. They sold a total of 325,416 shares worth more than $30,403,008.43. The most recent insider tranaction occured on April, 28th when CEO John M Evans sold 30,000 shares worth more than $1,139,400.00. Insiders at Beam Therapeutics own 0.7 % of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 4/28/2022.

Giuseppe Ciaramella Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2022Sell1,859$59.11$109,885.49115,614View SEC Filing Icon  
12/21/2021Sell25,104$85.69$2,151,161.76View SEC Filing Icon  
6/28/2021Sell78,580$107.35$8,435,563.00123,341View SEC Filing Icon  
See Full Table

Giuseppe Ciaramella Buying and Selling Activity at Beam Therapeutics

This chart shows Giuseppe Ciaramella's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $35.19
Low: $31.58
High: $35.86

50 Day Range

MA: $47.32
Low: $29.96
High: $63.11

2 Week Range

Now: $35.19
Low: $27.77
High: $138.52

Volume

1,198,405 shs

Average Volume

1,507,074 shs

Market Capitalization

$2.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.